Comparing the current results to its competitors, Ovid Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -88.31 %, despite the revenue increase by the most of its competitors of 20.5 %, recorded in the same quarter.
Ovid Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape for epilepsy and psychiatric medicines is fragmented, with no single dominant competitor. Competitors for OV329 include UCB, Jazz Pharmaceuticals plc, SK Biopharmaceuticals Inc., Harmony Biosciences, and Xenon Pharmaceuticals, Inc. In the area of KCC2 programs targeting psychosis associated with Parkinson’s disease and Lewy body dementia (LBD), schizophrenia, and mood disorders, Acadia Pharmaceuticals Inc. markets the only existing medicine for psychosis related to Parkinson’s disease and LBD. Axonis Therapeutics, Inc. is also developing KCC2 potentiators. Competition is influenced by factors such as clinical trial progress, regulatory approvals, and marketing capabilities. Competitors encompass pharmaceutical and biotechnology companies, academic institutions, and government agencies, many of which possess greater financial, technical, and human resources and more experience in drug development and regulatory processes.
June 17, 2024
Ovid Therapeutics Provides Insight into Takeda s Phase 3 Topline Study Results for Soticlestat in Rare Epileptic SyndromesIn a promising development in the field of rare epileptic syndromes, Ovid Therapeutics Inc. has shared significant insights into Takeda Pharmaceutical Company Limited s latest announcement regarding the Phase 3 clinical trials of soticlestat. Ovid Therapeutics, a pioneering biopharmaceutical firm dedicated to improving the lives of individuals impacted by rare epilepsies and brain conditions, has reported Takeda s topline data from two pivotal studies, namely SKYLINE and SKYWAY. These studies have been conducted to assess the efficacy of soticlestat as a potential treatment for Dravet syn...
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Moleculin Biotech Inc is a biopharmaceutical company that develops innovative cancer therapies by targeting key enzymes and signaling pathways involved in the progression of tumors. Their business model revolves around conducting preclinical and clinical trials to advance their drug candidates, with a focus on maximizing therapeutic impact and commercial potential.
Longeveron Inc's business model involves the development and commercialization of regenerative medicine products using mesenchymal stem cells for various medical conditions.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Sources:
Ovid Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ovid Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
